- Myasthenia gravis treatment options are becoming increasingly essential due to the rising prevalence of autoimmune neuromuscular disorders globally, with growing awareness and early diagnosis significantly boosting treatment adoption across healthcare systems
- The escalating demand for advanced therapies is driven by the growing incidence of generalized myasthenia gravis (gMG), increasing approvals of monoclonal antibodies and complement inhibitors, and improved access to neurology care
- North America dominated the myasthenia gravis treatment market with the largest revenue share of 41.6% in 2024, attributed to robust healthcare infrastructure, early adoption of biologics and novel therapies, and strong presence of leading pharmaceutical companies. The U.S. is experiencing substantial growth in new treatment initiations, driven by clinical advancements and favorable reimbursement policies
- Asia-Pacific is projected to be the fastest growing region in the myasthenia gravis treatment market, registering a CAGR of 13.7% from 2025 to 2032, due to increasing healthcare expenditures, improving access to neurological specialists, and heightened awareness of rare autoimmune diseases
- The proton radiation segment dominated the myasthenia gravis treatment market with a market share of 38.6% in 2024, driven by its superior ability to precisely target tumors while sparing surrounding healthy tissue. Its growing application in treating delicate and localized cancers—such as ocular, brain, and pediatric tumors—has contributed to strong clinical adoption and increasing preference among healthcare providers
